Psilocybin Medical Trial: The Healing Mushrooms (Medical Documentary) | Real Stories

Real Stories・2 minutes read

Researchers at Imperial College London are conducting a clinical trial using psilocybin to treat severe depression, with promising results showing remission in some participants after years of suffering. Despite potential benefits, limited access to psychedelic therapy due to regulations restricts many individuals from experiencing relief from depression and addiction.

Insights

  • Psilocybin, the active ingredient in magic mushrooms, is undergoing clinical trials at Imperial College London for severe treatment-resistant major depression, with potential to revolutionize psychiatry.
  • Psychedelic therapy, unlike traditional antidepressants, enables individuals like Andy to delve into root causes of depression, offering profound insights and long-term remission, yet access remains restricted due to regulations, hindering widespread benefits.

Get key ideas from YouTube videos. It’s free

Recent questions

  • Can magic mushrooms treat severe depression?

    British researchers are exploring the use of psilocybin, the active ingredient in magic mushrooms, to treat severe treatment-resistant major depression. This research is being conducted at Imperial College London, with the belief that psychedelics could revolutionize depression treatment and psychiatry.

  • What led to the classification of psychedelic drugs as Schedule 1?

    President Nixon's 1971 directive classified psychedelic drugs as Schedule 1, hindering research into their medical benefits since the 1960s. This classification limited the exploration of alternative treatments for conditions like severe depression.

  • How does psilocybin impact brain function?

    Psilocybin can mimic the effects of serotonin in regulating brain function, potentially offering more benefits for individuals with severe treatment-resistant major depression. This compound induces chaos in the brain, resetting it to a healthy mode of function, aiding in treating depression.

  • What are the key aspects of psychedelic therapy?

    Psychedelic therapy involves facing and integrating painful memories, resolving past traumas, and emphasizing resolution and love as key components to overcoming negative emotions. This therapy triggers intense emotions and memories, leading to profound realizations about past traumas and their impact on mental health.

  • What were the outcomes of the psychedelic therapy trial?

    Initial results from the psychedelic therapy trial showed promising outcomes, with roughly half of the participants achieving remission from depression after an average of 18 years of suffering. Some participants remained depression-free even after two years, highlighting the potential benefits of this treatment.

Related videos

Summary

00:00

Magic mushrooms for treating severe depression: A breakthrough

  • In 2012, British researchers sought to treat severe depression with magic mushrooms after obtaining permission following a three-year process.
  • Approximately 50% of individuals do not respond to antidepressants, with a significant portion facing the risk of suicide, prompting exploration of alternative treatments.
  • Psilocybin, the active ingredient in magic mushrooms, is being tested on patients with severe treatment-resistant major depression at Imperial College London.
  • LSD research in the 1950s and 1960s led to significant scientific papers, impacting attitudes and behaviors upon its availability to the public in the 1960s.
  • President Nixon's 1971 directive classified psychedelic drugs as Schedule 1, hindering research into their medical benefits since the 1960s.
  • Imperial College London is conducting the first clinical trial of psilocybin with the backing of the Medical Research Council.
  • The trial lead, Robin Carhart-Harris, believes psychedelics could revolutionize depression treatment and psychiatry.
  • Professor David Nutt highlights the role of serotonin in regulating brain function and how psilocybin can mimic its effects, potentially offering more benefits.
  • Patients in the trial, like John, have treatment-resistant depression, having tried multiple treatments without success.
  • The trial involves two doses of psilocybin, with the first aimed at testing tolerance and subsequent treatment days following a week later, lasting about six hours each.

24:09

Healing Trauma Through Psilocybin Therapy

  • Schedule 1 drugs require a home office license for research, stored securely in a locked safe bolted to the wall.
  • Psychoactive ingredient in magic mushrooms, psilocybin, requires a high dose of two and a half grams of mushroom material or a couple of hundred liberty cap magic mushrooms for recreational use.
  • Experiences with work and feelings of inadequacy were not the focus during sessions, instead delving into early childhood suffering and pain.
  • Facing repressed childhood demons is crucial for healing, as unresolved issues can cause ongoing suffering.
  • Resolution and love are emphasized as key to overcoming past traumas and negative emotions.
  • Psilocybin induces chaos in the brain, resetting it to a healthy mode of function, potentially aiding in treating depression.
  • London visit post-treatment showcases a newfound lightness and freedom from depressive thoughts.
  • Treatment brings up painful childhood memories, leading to a deep exploration of past traumas and their impact on mental health.
  • The treatment process involves facing and integrating painful memories to heal and move forward.
  • The therapy session triggers intense emotions and memories, leading to a profound realization about past traumas and their impact on mental health.

48:37

Psychedelic therapy reveals childhood fears in Andy.

  • Psychedelic doses can evoke childhood vulnerabilities and fears in adults, as seen in Andy's case.
  • Andy's fear of annihilation and rejection has been a lifelong struggle, indicating clinical significance.
  • Long-term therapy and dosing sessions are deemed necessary for substantial breakthroughs.
  • Andy's major issue is not depression but a lack of direction and reliance on others for guidance.
  • School was challenging for Andy, feeling alienated and disconnected from others.
  • Andy's childhood trauma in Clearland impacted his emotional well-being significantly.
  • Living consciously with past traumas is healthier than repressing them, leading to self-awareness.
  • Psychedelic treatment led to profound and dark realizations for Andy, potentially empowering him.
  • Despite initial positive results, Andy's depression resurfaced post-trial, affecting his family life.
  • Andy's reintegration therapy helped him reevaluate his childhood trauma and shift his perspective, leading to life-changing insights.

01:09:42

Psychedelic therapy offers hope for depression sufferers

  • Andy's high day session involved three parts: feeling unwanted by his father as a baby, criticized and controlled by his mother as a child, and reaching a healthy adult position of compassion and love.
  • The treatment Andy underwent allowed him to progress from feeling unwanted by his father to addressing his feelings towards his mother's criticism and control, with the hope of eventually reaching self-acceptance and love.
  • The psychedelic therapy Andy received provided insights into his depression, unlike antidepressants, which lack this aspect, offering the possibility of understanding and processing the root causes of depression.
  • Initial results from the treatment showed promising outcomes, with roughly half of the participants achieving remission from depression after an average of 18 years of suffering, with some remaining depression-free even after two years.
  • Despite the positive results, access to such treatments is limited due to regulations, denying many individuals the opportunity to benefit from psychedelic therapy, leading to continued struggles with depression and addiction.
Channel avatarChannel avatarChannel avatarChannel avatarChannel avatar

Try it yourself — It’s free.